Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ivonescimab + Tepotinib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ivonescimab | AK112|AK 112|AK-112|SMT112|SMT 112|SMT-112 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 137 VEGFA Antibody 6 | Ivonescimab is a bispecific antibody that binds PD-1 and VEGFA, potentially resulting in antitumor activity (PMID: 37593227). | |
| Tepotinib | Tepmetko | EMD1214063|EMD-1214063|EMD 1214063|MSC2156119|MSC-2156119|MSC2156119J | MET Inhibitor 59 | Tepmetko (tepotinib) selectively binds to the proto-oncogene hepatocyte growth factor receptor (HGFR or c-Met), which inhibits c-Met phosphorylation and disrupts c-Met-mediated signaling pathways, thereby suppressing tumor growth in tumor cells with activated or overexpression of c-Met protein (PMID: 32328660). Tepmetko (tepotinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|